Ensemble for evaluating diagnostic efficacy of non-invasive indices in predicting liver fibrosis in untreated hepatitis C virus population

Table 4 Diagnostic accuracy for fibronectin, aspartate aminotransferase to platelet ratio index, and fibrosis-4

Indices	S. Fibronectin, %	APRI, %	FIB-4, %
Fibrosis
Sensitivity	98.70	73.30	73.30
Specificity	100	88	96
Youdens index	0.987	0.613	0.693
AUROC	1	0.829	0.85
LR+	> 10	< 10	> 10
LR-	0.013	0.303	0.277
Mild fibrosis
Sensitivity	100	45.80	45.80
Specificity	96	88	96
Youdens index	0.96	0.338	0.418
AUROC	0.999	0.672	0.725
LR+	> 10	< 10	> 10
LR-	0	0.615	0.564
Moderate fibrosis
Sensitivity	92.20	80.40	82.40
Specificity	100	77.60	85.70
Youdens index	0.922	0.579	0.681
AUROC	0.993	0.836	0.853
LR+	> 10	< 10	< 10
LR-	0.0784	0.252	0.205
Severe fibrosis
Sensitivity	96.20	84.60	92.30
Specificity	98.60	62.20	71.60
Youdens index	0.948	0.468	0.639
AUROC	0.922	0.796	0.835
LR+	> 10	< 10	< 10
LR-	0.038	0.247	0.107

APRI: Aspartate aminotransferase to platelet ratio index; AUROC: Area under receiver operating characteristic curve; FIB-4: Fibrosis-4; LR+: Positive likelihood test; LR-: Negative likelihood test. Some of the values are converted into percentages. Cutoffs: Mild (> 110, > 0.824, > 1.90), moderate (> 140, > 1.19, > 2.45) and severe fibrosis (> 180, > 1.38, > 2.7), respectively.